RE:RE:RE:RE:RE:RE:New post on LinkedIn That's the transcript I believe.
Every day, there are 158 cancer diagnoses in Quebec, and 65 people die from it. If it's the number one killer in the province, a breakthrough could make a difference.
“We are very enthusiastic because I have been working in oncology for 35 years, and this is the first time that I have seen results,” says Dr. Richard Bliveau, researcher and doctor in biochemistry. “Often, we imagine something in research, but experimentation shows us that we have to adapt our hypothesis. With this platform, we had no surprises, that's what is surprising, the predictions we made have almost all been confirmed. It is the dream of the researcher. ”
Paul Lvesque, CEO of Theratechnologies, is as optimistic as Mr. Bliveau. "I am in the hands of American investors who looked at what we have and who were amazed by the quality of the data in the preclinical phase," he says.
Neutralize the enemy
We must find a cancer treatment more effective than chemotherapy, it is the sinews of war, according to the researcher.
“When you attack an enemy, you attack it with its weak points, so what we have identified is one of the weak points of the cancer cell,” explains Dr. Bliveau. “We use that entry route there for the attack. It's a bit like a missile guided by GPS technology, you target the explosive charge directly where the missile needs to explode, so the collateral damage is lower. ”
If Quebec succeeds in neutralizing cancer or in finding a solution that would be part of the heavy artillery in the fight against the disease, that would be to the credit of the people who identified the problem in the laboratory and who had it. developed subsequently, according to Mr. Lvesque.
"Fortunately we have these skills to do it, then if we go to marketing, we will see if we can market this on a global scale," he adds.
Since research and laboratory equipment are expensive, one of the main challenges in the deployment of oncology research is funding.
“But as long as the science continues to move in the same direction with the clinical data that we have seen, as the data becomes convincing, funding will follow,” notes Dr. Lvesque.
Mr. Bliveau points out that the project has received approval from the Food and Drug Administration (FDA), which is rare and remarkable, according to him. “It gives us a tactical and strategic advantage for development,” he says.
"Cancer is the number one public enemy, I think that everything we do in research to counter this enemy and reduce its impact is important and I think that this platform will reduce this impact. ”
https://www.journaldequebec.com/2021/11/18/bientot-un-remede-contre-le-cancer-1